Ambient ultrafine particles alter lipid metabolism and HDL anti-oxidant capacity in LDLR-null mice

Journal of Lipid Research

Volumn 54, Issue 6, 2013, Pages 1608-1615

  Li, Rongsong ^a,c   Navab, Mohamad ^c   Pakbin, Payam ^b   Ning, Zhi ^d   Navab, Kaveh ^c   Hough, Greg ^c   Morgan, Todd E ^b   Finch, Caleb E ^b   Araujo, Jesus A ^c   Fogelman, Alan M ^c   Sioutas, Constantinos ^b   Hsiai, Tzung ^a,c  

^a University of Southern California   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CITY UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN; HYDROXYICOSATETRAENOIC ACID; HYDROXYOCTADECADIENOIC ACID; LINOLEIC ACID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; SERUM AMYLOID A; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; AORTA ATHEROSCLEROSIS; AORTA SINUS; ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; LIPID METABOLISM; LIPID OXIDATION; MALE; MOUSE; NONHUMAN; PARTICULATE MATTER; PRIORITY JOURNAL; ULTRAFINE PARTICLE;

ATHEROSCLEROSIS; D-4F; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR-NULL;

ANIMALS; ANTIOXIDANTS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; DIETARY FATS; LIPID METABOLISM; LIPOPROTEINS, HDL; MICE; MICE, KNOCKOUT; OXIDATION-REDUCTION; PARTICULATE MATTER; PEPTIDOMIMETICS; RECEPTORS, LDL;

EID: 84877898035     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M035014     Document Type: Article

References (40)

1. Brook, R. D., B. Franklin, W. Cascio, Y. Hong, G. Howard, M. Lipsett, R. Luepker, M. Mittleman, J. Samet, S. C. Smith, Jr., et al. 2004. Air pollution and cardiovascular disease: a statement for healthcare professionals from the Expert Panel on Population and Prevention Science of the American Heart Association. Circulation. 109: 2655-2671. (Pubitemid 38720571)
2. Brook, R. D., S. Rajagopalan, C. A. Pope 3rd, J. R. Brook, A. Bhatnagar, A. V. Diez-Roux, F. Holguin, Y. Hong, R. V. Luepker, M. A. Mittleman, et al. 2010. Particulate matter air pollution and cardiovascular disease: an update to the scientific statement from the American Heart Association. Circulation. 121: 2331-2378.
3. Curtiss, L. K. 2009. Reversing atherosclerosis. N. Engl. J. Med. 360: 1144-1146.
4. Sardar, S. B., P. M. Fine, P. R. Mayo, and C. Sioutas. 2005. Size-fractionated measurements of ambient ultrafine particle chemical composition in Los Angeles using the NanoMOUDI. Environ. Sci. Technol. 39: 932-944.
5. Nel, A., T. Xia, L. Madler, and N. Li. 2006. Toxic potential of materials at the nanolevel. Science. 311: 622-627. (Pubitemid 43191298)
6. Zhang, Y., J. J. Schauer, M. M. Shafer, M. P. Hannigan, and S. J. Dutton. 2008. Source apportionment of in vitro reactive oxygen species bioassay activity from atmospheric particulate matter. Environ. Sci. Technol. 42: 7502-7509.
7. Araujo, J. A., B. Barajas, M. Kleinman, X. Wang, B. J. Bennett, K. W. Gong, M. Navab, J. Harkema, C. Sioutas, A. J. Lusis, et al. 2008. Ambient particulate pollutants in the ultrafine range promote early atherosclerosis and systemic oxidative stress. Circ. Res. 102: 589-596. (Pubitemid 351416760)
8. Navab, M., S. T. Reddy, B. J. Van Lenten, and A. M. Fogelman. 2011. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat. Rev. Cardiol. 8: 222-232.
9. Navab, M., R. Yu, N. Gharavi, W. Huang, N. Ezra, A. Lotfizadeh, G. M. Anantharamaiah, N. Alipour, B. J. Van Lenten, S. T. Reddy, et al. 2007. High-density lipoprotein: antioxidant and anti-inflammatory properties. Curr. Atheroscler. Rep. 9: 244-248. (Pubitemid 47629072)
10. Ansell, B. J., G. C. Fonarow, and A. M. Fogelman. 2007. The paradox of dysfunctional high-density lipoprotein. Curr. Opin. Lipidol. 18: 427-434. (Pubitemid 47051922)
11. Navab, M., S. T. Reddy, B. J. Van Lenten, G. M. Anantharamaiah, and A. M. Fogelman. 2009. The role of dysfunctional HDL in atherosclerosis. J. Lipid Res. 50(Suppl.): S145-S149.
12. Alwaili, K., Z. Awan, A. Alshahrani, and J. Genest. 2010. High-density lipoproteins and cardiovascular disease: 2010 update. Expert Rev. Cardiovasc. Ther. 8: 413-423.
13. Morgantini, C., A. Natali, B. Boldrini, S. Imaizumi, M. Navab, A. M. Fogelman, E. Ferrannini, and S. T. Reddy. 2011. Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes. Diabetes. 60: 2617-2623.
14. Navab, M., G. M. Anantharamaiah, S. Hama, D. W. Garber, M. Chaddha, G. Hough, R. Lallone, and A. M. Fogelman. 2002. Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation. 105: 290-292. (Pubitemid 34106174)
15. Misra, C., S. Kim, S. Shen, and C. Sioutas. 2002. A high flow rate, very low pressure drop impactor for inertial separation of ultrafine from accumulation mode particles. J. Aerosol Sci. 33: 735-752. (Pubitemid 34270474)
16. Morgan, T. E., D. A. Davis, N. Iwata, J. A. Tanner, D. Snyder, Z. Ning, W. Kam, Y. T. Hsu, J. W. Winkler, J. C. Chen, et al. 2011. Glutamatergic neurons in rodent models respond to nanoscale particulate urban air pollutants in vivo and in vitro. Environ. Health Perspect. 119: 1003-1009.
17. Verma, V., Z. Ning, A. K. Cho, J. J. Schauer, M. M. Shafer, and C. Sioutas. 2009. Redox activity of urban quasi-ultrafine particles from primary and secondary sources. Atmos. Environ. 43: 6360-6368.
18. Jiang, X. C., L. Masucci-Magoulas, J. Mar, M. Lin, A. Walsh, J. L. Breslow, and A. Tall. 1993. Down-regulation of mRNA for the low density lipoprotein receptor in transgenic mice containing the gene for human cholesteryl ester transfer protein. Mechanism to explain accumulation of lipoprotein B particles. J. Biol. Chem. 268: 27406-27412. (Pubitemid 24006464)
19. Imaizumi, S., V. Grijalva, M. Navab, B. J. Van Lenten, A. C. Wagner, G. M. Anantharamiah, A. M. Fogelman, and S. T. Reddy. 2010. L-4F differentially alters plasma levels of oxidized fatty acids resulting in more anti-inflammatory HDL in mice. Drug Metab. Lett. 4: 139-148.
20. Buga, G. M., M. Navab, S. Imaizumi, S. T. Reddy, B. Yekta, G. Hough, S. Chanslor, G. M. Anantharamaiah, and A. M. Fogelman. 2010. L-4F alters hyperlipidemic (but not healthy) mouse plasma to reduce platelet aggregation. Arterioscler. Thromb. Vasc. Biol. 30: 283-289. [Erratum. 2010. Arterioscler. Thromb. Vasc. Biol. 30: e174.]
21. Navab, M., S. Y. Hama, G. P. Hough, G. Subbanagounder, S. T. Reddy, and A. M. Fogelman. 2001. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J. Lipid Res. 42: 1308-1317. (Pubitemid 32744255)
22. Shih, D. M., Y. R. Xia, X. P. Wang, E. Miller, L. W. Castellani, G. Subbanagounder, H. Cheroutre, K. F. Faull, J. A. Berliner, J. L. Witztum, et al. 2000. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J. Biol. Chem. 275: 17527-17535. (Pubitemid 30430794)
23. Tangirala, R. K., E. M. Rubin, and W. Palinski. 1995. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J. Lipid Res. 36: 2320-2328.
24. Eckerson, H. W., C. M. Wyte, and B. N. La Du. 1983. The human serum paraoxonase/arylesterase polymorphism. Am. J. Hum. Genet. 35: 1126-1138. (Pubitemid 14201166)
25. Navab, M., S. T. Reddy, G. M. Anantharamaiah, G. Hough, G. M. Buga, J. Danciger, and A. M. Fogelman. 2012. D-4F-mediated reduction in metabolites of arachidonic and linoleic acids in the small intestine is associated with decreased inflammation in low-density lipoprotein receptor-null mice. J. Lipid Res. 53: 437-445.
26. Watson, A. D., J. A. Berliner, S. Y. Hama, B. N. La Du, K. F. Faull, A. M. Fogelman, and M. Navab. 1995. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96: 2882-2891.
27. Peluso, I., G. Morabito, L. Urban, F. Ioannone, and M. Serafini. 2012. Oxidative stress in atherosclerosis development: the central role of LDL and oxidative burst. Endocr. Metab. Immune Disord. Drug Targets. 12: 351-360.
28. Funk, C. D., and T. Cyrus. 2001. 12/15-lipoxygenase, oxidative modification of LDL and atherogenesis. Trends Cardiovasc. Med. 11: 116-124. (Pubitemid 33070334)
29. Tsai, D. H., N. Amyai, P. Marques-Vidal, J. L. Wang, M. Riediker, V. Mooser, F. Paccaud, G. Waeber, P. Vollenweider, and M. Bochud. 2012. Effects of particulate matter on inflammatory markers in the general adult population. Part. Fibre Toxicol. 9: 24.
30. Li, R., D. Mittelstein, W. Kam, P. Pakbin, Y. Du, Y. Tintut, M. Navab, C. Sioutas, and T. Hsiai. 2013. Atmospheric ultrafine particles promote vascular calcification via the NF-kappaB signaling pathway. Am. J. Physiol. Cell Physiol. 304: C362-C369.
31. Li, R., Z. Ning, R. Majumdar, J. Cui, W. Takabe, N. Jen, C. Sioutas, and T. Hsiai. 2010. Ultrafine particles from diesel vehicle emissions at different driving cycles induce differential vascular pro-inflammatory responses: implication of chemical components and NF-kappaB signaling. Part. Fibre Toxicol. 7: 6.
32. Patel, P. J., A. V. Khera, K. Jafri, R. L. Wilensky, and D. J. Rader. 2011. The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease. J. Am. Coll. Cardiol. 58: 2068-2075.
33. Zadelaar, S., R. Kleemann, L. Verschuren, J. de Vries-Van der Weij, J. van der Hoorn, H. M. Princen, and T. Kooistra. 2007. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler. Thromb. Vasc. Biol. 27: 1706-1721. (Pubitemid 47207165)
34. Efrat, M., and M. Aviram. 2010. Paraoxonase 1 interactions with HDL, antioxidants and macrophages regulate atherogenesis-a protective role for HDL phospholipids. Adv. Exp. Med. Biol. 660: 153-166.
35. Mackness, B., and M. Mackness. 2010. Anti-inflammatory properties of paraoxonase-1 in atherosclerosis. Adv. Exp. Med. Biol. 660: 143-151.
36. Säemann, M. D., M. Poglitsch, C. Kopecky, M. Haidinger, W. H. Horl, and T. Weichhart. 2010. The versatility of HDL: a crucial anti-inflammatory regulator. Eur. J. Clin. Invest. 40: 1131-1143.
37. Forte, T. M., G. Subbanagounder, J. A. Berliner, P. J. Blanche, A. O. Clermont, Z. Jia, M. N. Oda, R. M. Krauss, and J. K. Bielicki. 2002. Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice. J. Lipid Res. 43: 477-485. (Pubitemid 34252278)
38. Van Lenten, B. J., A. C. Wagner, C. L. Jung, P. Ruchala, A. J. Waring, R. I. Lehrer, A. D. Watson, S. Hama, M. Navab, G. M. Anantharamaiah, et al. 2008. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J. Lipid Res. 49: 2302-2311.
39. Smith, J. D. 2010. Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler. Thromb. Vasc. Biol. 30: 151-155.
40. Snedecor, G. W., and W. G. Cochran. 1989. Statistical Methods. 8th edition. Iowa State University Press, Ames, Iowa.